UniQure Announces New Data in Phase I/II Clinical Trial

______________________________________________________________________________Note: The following is edited from a press release from UniQure. Read the full press release in it’s entirety here.UniQure announced new and updated results during the American Society of Hematology (ASH) meeting in relation to its ongoing, dose-ranging Phase I/II trial of AMT-060. AMT-060 is UniQure’s proprietary, investigational gene therapy for patients with severe hemophilia B. […]

Sangamo Biosciences Announces Plans to File for New Investigational Drug

______________________________________________________________________________Note: The following is edited from a press release from Sangamo Biosciences. Read the full press release in its entirety here.Sangamo Biosciences presented data during the recent American Society of Hematology (ASH) Annual Meeting regarding preclinical and manufacturing data of SB-525, its gene therapy program for hemophilia A.“We have developed an improved gene therapy vector […]

Spark Therapeutics Shares Updated Phase I/II Clinical Trial Data

______________________________________________________________________________Note: The following is edited from a press release from Spark Therapeutics. Read the full press release in it’s entirety here..Spark Therapeutics and Pfizer announced updated results from the Phase 1/2 study of SPK-9001, an investigational recombinant gene transfer product in hemophilia B, at the 58th American Society of Hematology (ASH) Annual Meeting, in San […]

Alnylam Presents Phase I Clinical Drug Trial Data at ASH 2016

 Note: The following is an excerpt from a press release from Alnylam Pharmaceuticals, Inc. regarding news from their recent presentation at the American Society of Hematology (ASH) Annual Meeting. The original article can be read in its entirety here.______________________________________________________________________________Alnylam Pharmaceuticals, Inc. presented data from the phase 1 study of fitusiran at the ASH meeting. The […]